United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Program

Second UHeart™ recipient recovering after a successful transplantUThymoKidney™ demonstrates normal function during a 61-day studyHuman xenotransplant clinical studies could begin in 2025SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--$UTHR #xenotransplantation--United Therapeutics Corporation (Na...

Related Keywords

United States ,Americans ,Leigh Peterson ,David Ayares ,Lawrence Faucette ,University Of Alabama At Birmingham ,Exchange Commission ,Langone Medical Center ,Services Administration ,Product Development Xenotransplantation At United Therapeutics ,United Therapeutics Corporation Nasdaq ,University Of Maryland Medical Center ,United Therapeutics Corporation ,Drug Administration ,Langone Health ,Us Health Resources ,University Of Maryland Medicine ,United Therapeutic ,Maryland Medicine ,Successful Xenoheart Transplant Conducted ,Maryland Medical ,Executive Vice President ,Product Development ,United Therapeutics ,Longest Documented Case ,Xeno Organ Function ,Human Body ,Medical Center ,Chief Scientific Officer ,United Therapeutic Revivicor ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,